Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

PathAI Announces Exclusive Collaboration with Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics

PathAI

PathAI, Inc., a leading AI-powered precision pathology company, today announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion diagnostics. Building upon the success of their initial partnership announced in October of 2021, this expanded collaboration will provide an integrated and streamlined solution for biopharma sponsors looking to develop AI-enabled companion diagnostics. Under this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space. RTD will work exclusively with PathAI for a pre-specified term as the sole external algorithm development company for AI-powered companion diagnostics, while retaining the ability to continue to develop its own algorithms for companion diagnostics. PathAI will retain the ability to freely develop algorithms outside of companion diagnostics. RTD and PathAI will create an integrated CDx assay, plus algorithm development process, to provide biopharma sponsors a seamless solution for AI-enabled companion diagnostics. With the increasing investment in immuno-oncology (IO) and now antibody drug conjugates (ADCs), the need for diagnostic tools that are optimized for patient selection will be critical for development, regulatory, and commercial success. "This collaboration with Roche is a testament to our shared commitment to advancing the field of digital pathology and AI-enabled diagnostics for both drug development and clinical care,” said Dr. Andy Beck, CEO and Co-Founder of PathAI. “High medical value diagnostic products with seamless integration into the laboratory workflow will accelerate the transition to digital pathology as the standard to aid clinicians in diagnosis and biomarker characterization." These co-developed, AI-enabled assays will be commercialized globally through Roche’s navify® Digital Pathology platform. PathAI will continue to distribute its AISight ® Image Management System (IMS), and its broad portfolio of algorithmic products. “As the market leader in companion diagnostics, we strive to continuously bring new innovations in personalized healthcare,” said Jill German, Head of Roche Tissue Diagnostics. “This collaboration with PathAI will allow us to accelerate our ability to meet the demand from biopharma companies looking to develop AI-enabled companion diagnostics, and provide them with a powerful end-to-end solution in the pursuit of precision therapeutics.” To learn more about this partnership, contact PathAI ( BD@PathAI.com ) to organize a meeting. About PathAI, Inc.: PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications. PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

February 13, 2024 10:00 AM Eastern Standard Time

Creo Medical Group expands reach of Speedboat UltraSlim; announces tie-up with Abu Dhabi university

Creo Medical Group PLC

Creo Medical Group CEO Craig Gulliford joined Proactive's Stephen Gunnion following the deployment of the Speedboat UltraSlim device in the Asia Pacific region, marking a significant milestone for the company. The Speedboat UltraSlim, a culmination of years of development, miniaturizes laparoscopic advanced energy capabilities into a compact device enhancing endoscopic surgery. This innovation enables precise surgical procedures with minimal invasiveness, targeting precancerous and cancerous lesions in the gastrointestinal tract. Gulliford highlighted the device's successful clinical applications in various regions, including the US, South America, Europe, and recently at the Prince of Wales Hospital in Hong Kong, focusing on stomach and colon lesions. The technology aims to reduce the need for conventional surgery, offering a safer alternative with lower complication rates. Additionally, Creo announced a strategic collaboration with Khalifa University of Science and Technology in Abu Dhabi to develop intellectual property and expand its technological reach into the Middle East. This partnership aims to foster innovation and enhance medical outcomes, reinforcing Creo Medical's commitment to advancing medical technology and improving patient care globally. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 12, 2024 10:00 AM Eastern Standard Time

Video

Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to highlight certain significant favorable market developments creating new opportunities to widen its funnel of potential users of Vivos’ oral appliance therapies. This comes after the U.S. FDA granted, for the first time ever, a clearance to the Vivos CARE appliances to treat moderate and severe OSA in adults, (18 years of age and older) with positive airway pressure and/or myofunctional therapy, as needed. Huntsman highlighted several other factors contributing to the positive market conditions for Vivos. The recent discontinuation of many devices by Philips Respironics is expected to disrupt the supply chain, potentially affecting patient care. Additionally, the recalls of continuous positive airway pressure (CPAP) devices have left millions of OSA sufferers searching for alternative treatments. United Healthcare's recognition of oral appliance therapy as a prerequisite for surgical treatment in adult patients with moderate to severe OSA is another important development. These factors are collectively creating a significant opportunity for Vivos to expand its user base and offer effective treatment options to those in need. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

February 12, 2024 09:24 AM Eastern Standard Time

Video

Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Andrew Reynolds as its newest Managing Director.

Roberts & Ryan, Inc.

Andrew Reynolds joins Roberts & Ryan as Managing Director and has more than 30 years of experience in equity trading, capital markets, portfolio management, options & derivatives, sales & business development, investor relations, and corporate compliance. Prior to joining Roberts & Ryan, Mr. Reynolds was Head of Equity Trading and a Registered Principal at Tullett Prebon and KCCI Ltd. Before that, he was Head Trader and Floor Broker at Tradition North America and R.J. Murphy & Associates. Prior to that, he was Head Trader at Preferred Technology. Mr. Reynolds began his career as an Options Clerk at Pershing, LLC. “Andrew brings extensive experience in equity trading and represents Roberts & Ryan’s commitment to providing best in class service and execution,” said James McDevitt, Roberts & Ryan’s Senior Director of Equity Sales and Trading, Capital Markets. “He will be a tremendous advocate for our social mission of supporting veterans and their families. I’m very excited to have him join our team.” Mr. Reynolds is a member of the Securities Traders Association (STA), the Securities Traders Association of New York (STANY), Philadelphia Traders (ITAP), and the National Investor Relations Institute (NIRI). He holds SIE and FINRA Series 7, 24, 25, 55, 57 & 63 licenses. Mr. Reynolds served as a Technical Warfare Specialist, Team Leader, and Group Leader in the 25 th Infantry Division of the United States Army and is a graduate of Archbishop Ryan in Philadelphia. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

February 12, 2024 09:00 AM Eastern Standard Time

Image

Building on success of first marketing campaign, 1606 Corp launches second one with Cannasite

1606 Corp.

1606 Corp CEO Greg Lambrect discussed the company's innovative marketing campaign in collaboration with its ISO partner, Cannasite, in an interview with Steve Darling from Proactive. The campaign is designed to engage Cannasite's extensive network of over 300 clients through targeted outreach, including email and calls. Following the success of their December marketing initiative for ChatCBDW with Cool Blue Distribution, Lambrect emphasized that the new campaign with Cannasite comes with higher expectations. The primary goal of the campaign is to expand the reach within the online brand community and solidify ChatCBDW's position as a pivotal tool in revolutionizing customer service and sales processes. Cannasite, a leading provider of web design and digital marketing services in the cannabis industry, has a strong client base and significant industry connections. Their partnership with 1606 Corp aims to revolutionize the AI merchandising landscape in the cannabis sector. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 12, 2024 08:22 AM Eastern Standard Time

Video

Poolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapies

Poolbeg Pharma PLC

Poolbeg Pharma Plc chief business officer David Allmond joined Proactive's Stephen Gunnion with details of independent research that confirms the massive market potential for Poolbeg's POLP 001 in cancer immunotherapies. This asset is being explored for its ability to potentially prevent or treat cytokine release syndrome (CRS), a significant side effect of cancer immunotherapies. With the cancer immunotherapy market expected to reach $140 billion by 2030, POLB 001 presents an over $10 billion opportunity if successful. Additionally, Allmond elaborated on Poolbeg's increasing emphasis on rare and orphan diseases, leveraging its ongoing programs in influenza with POLB 001, obesity, metabolic conditions, and AI-driven discovery for novel targets. The company is actively considering strategies to acquire near-stage commercial or in-market products in this high unmet need, limited competition sector. This approach aligns with Poolbeg's evolution towards a commercial-stage organization, aiming to generate revenue and continue its growth trajectory. Furthermore, Allmond explained how POLB 001 fits into the rare orphan disease space, given its potential applications in orphan cancers where immunotherapies have shown success. Poolbeg's strategic pivot towards rare and orphan diseases complements its existing portfolio, aiming for a dual-track growth strategy focusing on both its current programs and commercial opportunities in the rare and orphan disease market. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 12, 2024 08:03 AM Eastern Standard Time

Video

Creo Medical ends "pivotal" 2023 year with clear path to cashflow breakeven

Creo Medical Group PLC

Creo Medical Group CEO Craig Gulliford tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company. Amid challenging market conditions, Creo successfully secured crucial funding, setting a foundation for enhanced operational focus rather than fundraising efforts. Key milestones included the launch of the Speedboat UltraSlim, a significant advancement in minimising medical device size, which led to the company's largest quarter in orders and technology uptake. This innovation, alongside the early market release of selected products, received positive feedback and significant regulatory clearances in the US and Europe, propelling Creo towards a robust setup for 2024. Furthermore, Creo announced progress with its SpydrBlade and MicroBlate programs, showcasing advancements in surgical technology and partnerships with leading robotic surgery firms. Financially, Creo reported a 13% revenue increase to £30.8 million and a 10% reduction in operating costs, reflecting strategic shifts towards more cost-effective and revenue-generating operations. These developments signal Creo's transition into a fully commercial business, with a clear path to cash flow breakeven by 2025. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 12, 2024 07:43 AM Eastern Standard Time

Video

BlackRock Acquires Stake In Cardio Diagnostics

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga BlackRock (NYSE: BLK) has acquired a minor stake in Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company. In BlackRock’s 13G filing on Feb. 2, they disclosed ownership representing 5.2% of Cardio Diagnostics. Fintel reports that the average one-year price target for Cardio Diagnostics is $6.12, and forecasts range from a low of $4.04 to a high of $8.40. Cardio Diagnostics had Weighted-Average Shares Outstanding (Diluted) of 11.90 million for the most recently reported fiscal quarter, ending Sept. 30, 2023. Cardio Diagnostics’ stock has an ownership structure of institutional, retail and individual investors. About 1.84% of the company’s stock is owned by institutional investors, while 18.58% is owned by insiders. About 79.58% is owned by public companies and individual investors. Prelude Capital Management, Geode Capital Management and Vanguard Group are the biggest institutional shareholders, with 121,000, 75,483 and 64,022 shares, respectively. About Cardio Diagnostics Cardio Diagnostics was formed to develop and commercialize clinical tests that leverage artificial intelligence-driven technology to combat cardiovascular disease. The company is behind PrecisionCHD, the first integrated genetic-epigenetic test for the detection of coronary heart disease (CHD), the most common type of heart disease and the cause of most heart attacks. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence (AI), along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD. Cardio Diagnostics has also developed Epi+Gen CHD, a powerful test that predicts the three-year risk for a CHD event, mainly a heart attack. Powered by AI-driven integrated genetics and epigenetics, the tool enables more effective decision-making and earlier interventions. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

February 09, 2024 08:30 AM Eastern Standard Time

Cannara Biotech CFO Nicholas Sosiak: Unveiling Success Strategies and Future Plans

Cannara Biotech Inc

Cannara Biotech Inc CFO Nicholas Sosiak joined Steve Darling from Proactive to provided valuable insights into the company's success in the cannabis industry. Cannara, based in Montreal, Canada, is a licensed producer with two facilities totaling 1.6 million square feet, with a strong focus on quality and cost-efficiency, thanks in part to Quebec's low electricity costs. Sosiak discussed the company's strategic acquisitions, including the purchase of a 1 million square foot cannabis facility for $27 million, significantly below its initial cost. Cannara Biotech Inc. has also developed three in-house brands: Tribal, Nugs, and Orchid CBD, each catering to specific market niches. The company places a strong emphasis on consistency and quality to drive brand loyalty among consumers. As CFO, Sosiak combines his financial expertise with a passion for the cannabis industry. His leadership has contributed to the company's impressive 60% increase in net revenue. Looking ahead to 2024, Cannara Biotech plans to capitalize on its existing markets, introduce new products, and expand into untapped regions. Sosiak expressed optimism about the potential for international growth, particularly in the US market, once regulatory barriers are addressed. Cannara Biotech Inc. is currently traded on the TSXV (LOVE) and OTCQB (LOVFF), with plans to enhance visibility among US investors in the future. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 08, 2024 09:37 AM Eastern Standard Time

Video

1 ... 55 56 57 58 59 ... 302